Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year.
Shares of the health care giant slid in early trading Tuesday after it also reported better-than-expected first-quarter earnings and hiked its dividend but chopped an earnings forecast it had debuted in January.
